The association of non-small-cell lung cancer, focal segmental glomerulosclerosis, and platelet dysfunction

American Journal of the Medical Sciences

Volumn 324, Issue 3, 2002, Pages 161-165

  Lin, Fang Chi ^a   Chen, Jinn Yang ^a   Yang, An Hang ^a   Chang, Shi Chuan ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Bleeding time; Focal segmental glomerulosclerosis; Lung cancer; Nephrotic syndrome; Paraneoplastic syndrome

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DIURETIC AGENT; GEMCITABINE; HYPERTENSIVE AGENT;

ADULT; ARTICLE; BLEEDING TIME; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MALE; NEPHROTIC SYNDROME; PARANEOPLASTIC SYNDROME; THORACOCENTESIS; THROMBOCYTE DYSFUNCTION; TREATMENT OUTCOME;

EID: 0036746454     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200209000-00008     Document Type: Article

References (16)

1. Coltharp WH, Lee SM, Miller RF, et al. Nephrotic syndrome complicating adenocarcinoma of the lung with resolution after resection. Ann Thorac Surg 1991;51:308-9.
2. Shikata Y, Hayashi Y, Yamazaki H, et al. Effectiveness of radiation therapy in nephrotic syndrome associated with advanced lung cancer. Nephron 1999;83:160-4.
3. Konoshita T, Itoh M, Hatakeyama S, et al. Nephrotic syndrome due to focal glomerulosclerosis and undifferentiated carcinoma. Clin Nephrol 2000;54:404-8.
4. Kitano S, Masuda J, Kuroiwa S, et al. Poorly differentiated adenocarcinoma of the rectum in a nephrotic patient with focal segmental glomerulosclerosis. Jpn J Surg 1984;14:155-8.
5. Hagedorn AB, Bowie EJ, Elveback LR, et al. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 1974;49:647-53.
6. Perlin CE, Scialla LS, Connor R. Blood coagulation profiles in patients with carcinoma of lung cancer. Mil Med 1982;147:296-8.
7. Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 1997;33:50-5.
8. Kristensen SD, Bath PM, Gladwin AM, et al. The relationship between increased platelet count and megakaryocyte size in bronchia carcinoma. Br J Haematol 1992;81:247-51.
9. Fer MF, McKinney TD, Richardson RL. Cancer and the kidney: renal complications of neoplasms. Am J Med 1981;71:704-18.
10. Brady HR, O'Meara YM, Brenner BM. The major glomerulopathies. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, editors. Harrison's principles of internal medicine, 14th ed. New York: McGraw-Hill; 1998. p. 1536-45.
11. Boon ES, Vrij AA, Nieuwhof C, et al. Small cell lung cancer with paraneoplastic nephrotic syndrome. Eur Respir J 1994;7:1192-3.
12. Fraser RS, Muller NL, Colman N, et al. Pulmonary carcinoma. In Fraser RS, Muller NL, Colman N, et al, editors. Fraser and Pare's diagnosis of diseases of the chest. 4th ed. Philadelphia: WB Saunders; 1999. p. 1069-228.
13. Harker LA, Slichter SJ. The bleeding time as a screening test for revaluation of platelet function. N Engl J Med 1972;287:155-9.
14. Buchanan GR. Quantitative and qualitative platelet disorders. Clin Lab Med 1999;19:71-87.
15. Handin RI. Bleeding and thrombosis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, editors. Harrison's principles of internal medicine, 14th ed. New York: McGraw-Hill; 1998. p. 339-45.
16. Broyer M, Meyrier A, Niaudet P, et al. Minimal changes and focal segmental glomerular sclerosis. In Davison AM, Cameron JS, Grunfeld JP, et al, editors. Oxford textbook of clinical nephrology, 2nd ed. Oxford (UK): Oxford University Press; 1998. p. 493-536.